Interactions of amphetamine analogs with human liver CYP2D6

Biochemical Pharmacology

Volumn 53, Issue 11, 1997, Pages 1605-1612

  Wu, Dafang ^a   Victoria Otton, S ^a   Inaba, Tadanobu ^c   Kalow, Werner ^c   Sellers, Edward M ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c NONE

Author keywords

Amphetamine; CYP2D6; Human liver microsomes; In vitro screening; MDMA; Methamphetamine

Indexed keywords

AMPHETAMINE DERIVATIVE; DEXTROMETHORPHAN;

ARTICLE; COMPETITIVE INHIBITION; DEMETHYLATION; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; LIVER MICROSOME; PHENOTYPE; PRIORITY JOURNAL;

AMPHETAMINES; BINDING, COMPETITIVE; CYTOCHROME P-450 CYP2D6; HUMANS; MICROSOMES, LIVER; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SUBSTRATE SPECIFICITY;

EID: 0343145695     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00014-2     Document Type: Article

References (43)

1. Eichelbaum M and Gross AS, The genetic polymorphism of debrisoquine/sparteine metabolism - Clinical aspects. Pharmacol Ther 46: 377-394, 1990.
2. Daly AK, Cholerton S, Gregory W and Idle JR, Metabolic polymorphisms. Pharmacol Ther 57: 129-160, 1993.
3. Brosen K and Gram LF, Clinical significance of the sparteine/ debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36: 537-547, 1989.
4. Kroemer HK and Eichelbaum M, Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56: 2285-2298, 1995.
5. Gonzalez FJ and Meyer UA, Molecular genetics of the debrisoquine-sparteine polymorphism. Clin Pharmacol Ther 50: 233-238, 1991.
6. Inaba T, Tyndale RF and Mahon WA, Quinidine: Potent inhibition of sparteine and debrisoquine oxidation in vivo. Br J Clin Pharmacol 22: 199-200, 1986.
7. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ and Smith RA, Dextromethorphan: Enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 51: 647-655, 1992.
8. Otton SV, Wu D, Joffe RT and Sellers EM, Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 53: 401-409, 1993.
9. Dring LG, Smith RL and Williams RT, The metabolic fate of amphetamine in man and other species. Biochem J 116: 425-435, 1970.
10. Smith RL, Introduction to special issue (human genetic variations in oxidative drug metabolism). Xenobiotica 16: 361-365, 1986.
11. Kitchen I, Tremblay JA, Dring LG, Idle JR, Smith RL and Williams RT, Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 7: 397-404, 1979.
12. Glennon RA, Stimulus properties of hallucinogenic phenalkylamines and related designer drugs: Formulation of structure-activity relationships. NIDA Res Monogr 94: 43-67, 1989.
13. Sannerud CA, Brady JV and Griffiths RR, Self-injection in baboons of amphetamines and related designer drugs. NIDA Res Monogr 94: 30-42, 1989.
14. Cimbura G, PMA deaths in Ontario. Can Med Assoc J 110: 1263-1267, 1974.
15. Sellers EM, Martin P, Roy M and Sellers EA, Amphetamine. Body temperature regulation, drug effects and therapeutic implications. In: Modern Pharmacology-Toxicology (Eds. Lomax P and Schonbaum E), Vol. 16, pp. 461-498. Marcel Dekker, New York, 1979.
16. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA and Chu TYY, The demethylenation of methylenedioxymethamphetamine ("Ectasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47: 1151-1156, 1994.
17. Hiramatsu M, Kumagai Y, Unger SE and Cho AK, Metabolism of methylenedioxyamphetamine: Formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 254: 521-527, 1990.
18. Zhao A, Castagnoli N, Ricaurte GA, Steele T and Martello M, Synthesis and neurotoxicological evaluation of putative metabolites of the serotoninergic neurotoxin 2-(methyl-amino)-1-[3,4-(methylenedioxy)phenyl] propane [(methyl-enedioxy)methamphetamine]. Chem Res Toxicol 5: 89-94, 1992.
19. Dougan DFH, Duffield AM, Duffield PH and Wade DN, Stereoselective accumulation of metabolites of amphetamine in rat striatum and hypothalamus. Br J Pharmacol 88: 285-290, 1986.
20. Coutts RT, Prelusky DB and Baker GB, Determination of amphetamine, norephedrine and their phenolic metabolites in rat brain by gas chromatography. J Pharm Sci 73: 808-812, 1989.
21. Hoffman AR, Sastry BVR and Axelrod J, Formation of α-methyldopamine ('catecholamphetamine') from p-hydroxyamphetamine by rat brain microsomes. Pharmacology 19: 256-260, 1979.
22. Burde RM and Thompson HS, Hydroxyamphetamine: A good drug lost? Am J Ophthalmol 111: 100-102, 1991.
23. Fonne-Pfister R, Bargetzi MJ and Meyer UA, MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufl, P450dbl) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 148: 1144-1150, 1987.
24. Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ and Niznik HB, Neuronal cytochrome P450IID1 (debrisoquine/ sparteine type): Potent inhibition of activity by (-)cocaine and nucleotide sequence identity of human hepatic P450 gene CYP2D6. Mol Pharmocol 40: 63-68, 1991.
25. Liccione JJ and Maines MD, Manganese-mediated increase in the rat brain mitochondrial cytochrome P-450 and drug metabolism activity: Susceptibility of the striatum. J. Pharmacol Exp Ther 248: 222-228, 1989.
26. Lin LY, Kumagai Y and Cho AK, Enzymatic and chemical demethylenation of (Methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem Res Toxicol 5: 401-406, 1992.
27. Campbell ME, Grant DM, Inaba T and Kalow W, Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P450 in human liver microsomes. Drug Metab Dispos 15: 237-249, 1987.
28. Tyndale RF, Inaba T and Kalow W, Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P450IID1) in vitro. Drug Metab Dispos 17: 334-340, 1989.
29. Tyndale RF, Gonzalez FJ, Hardwick JP, Kalow W and Inaba T, Sparteine metabolism capacity in human liver: Structural variants of human P450IID6 as assessed by immunochemistry. Pharmacol Toxicol 67: 14-18, 1990.
30. Gonzalez FJ, Vilbois F, Hardwick JP, McBride OW, Nebert DW, Gelboin HV and Meyer UA, Human debrisoquine 4-hydroxylase (P450IID1):cDNA and deduced amino acid sequence and assignment of the CYP2D6 locus to chromosome 22. Genomics 2: 174-179, 1988.
31. Tyndale RF, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA and Gonzalez FJ, Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: Possible association with the poor metabolizer phenotype. Pharmacogenetics 1: 26-32, 1991.
32. Ellis SW, Ching MS, Watson PF, Henderson CJ, Simula AP, Lennard MS, Tucker GT and Woods HF, Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochem Pharmacol 44: 617-620, 1992.
33. Zanger UM, Vilbois F, Hardwick JP and Meyer UA, Absence of hepatic cytochrome P450 bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447-5454, 1988.
34. Broly F, Libersa C, Lhermitte M, Bechtel P and Dupuis B, Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 28: 29-36, 1989.
35. Dixon M and Webb EC, Enzymes, 3rd Ed, pp. 345-352. Longmans, Green & Co. Ltd., London, 1979.
36. Tallarida RJ and Murray RB, Pharmacological calculation system based on "A Manual of pharmacological calculations with computer programs." Springer, New York, 1986.
37. Leatherbarrow RJ, ENZFITTER, a non-linear regression data analysis program for the IBM PC. Biosoft, Cambridge, U.K., 1987.
38. Nichols DE, Shulgin AT and Dyer DC, Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives. Life Sci 21: 569-576, 1977.
39. Otton SV, Crew HK, Leonard MS, Tucker GT and Woods HF, The use of quinidine inhibition to define the role of the sparteine/debrisoquine P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 247: 242-247, 1988.
40. Schmid B, Bircher J, Preisig R and Kupfer A, Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 38: 618-624, 1985.
41. Kumagai Y, Lin LY, Hiratsuka A, Narimatsu S, Suzuki T, Yamada H, Oguri K, Yoshimura H and Cho AK, Participation of cytochrome P4502B and 2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats. Mol Pharmacol 45: 359-365, 1994.
42. Wilkinson CF, Murray M and Marcus CB, Interactions of methylenedioxyphenyl compounds with cytochrome P450 and effects on microsomal oxidation. Rev Biochem Toxicol 6: 27-63, 1984.
43. Brady JF, DiStefano EW and Cho AK, Spectral and inhibitory interactions of (±)-3,4-methylenedioxyamphetamine (MDA) and (±)-3,4-methylenedioxymethamphetamine (MDMA) with rat hepatic microsomes. Life Sci 39: 1457-1464, 1986.